Hypertension Clinical Trial
Official title:
Efficacy and Safety of the Dietary Approaches to Stop Hypertension (DASH) Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study
Verified date | October 2014 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
More than two-thirds of US adults with chronic kidney disease (CKD) have uncontrolled
hypertension. Both hypertension and CKD are major independent risk factors for
cardiovascular disease, which is the leading cause of death in the US. Fortunately, lowering
blood pressure to recommended treatment targets not only slows the progression of CKD, but
also improves cardiovascular outcomes. Controlling hypertension in this patient population,
however, can be quite challenging. A lifestyle modification that effectively reduces blood
pressure in both pre-hypertensive and hypertensive adults is the Dietary Approaches to Stop
Hypertension (DASH) diet.
The purpose of this pilot study is to (1) determine the extent to which the DASH diet lowers
blood pressure in hypertensive adults with moderate chronic kidney disease (CKD) (estimated
glomerular filtration rate [eGFR] 30-59 ml/min/1.73m2) and (2) establish that the DASH diet
can be safely consumed by this patient population.
Status | Completed |
Enrollment | 42 |
Est. completion date | August 2014 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - =18 years old - eGFR 30-59 ml/min/1.73m2 - SBP = 130 mmHg or DBP = 80 mmHg - willing to eat one meal on-site 5 days/week Exclusion Criteria: - baseline potassium >4.6 mEq/L while not taking potassium supplements (if potassium is = 5.0 while taking potassium supplements, a potassium of 4.6 or less must be demonstrated off supplements - evidence of hyperkalemia (>5.1 mEq/L) within last 6 months - = 0.5 mg/dl increase in serum creatinine in past 6 months - albumin-to-creatinine ratio > 200 mg/mmol - insulin requiring or poorly controlled diabetes mellitus - cardiovascular event within previous 6 months - change in anti-hypertensive medications in last 2 weeks, or anticipated medication change during study period - unwillingness to eat only study food for 21 day study period - unwillingness or inability to discontinue vitamin and mineral supplements or antacids containing potassium, magnesium or calcium - use of aldosterone antagonist - use of oral corticosteroids - alcohol intake >14 drinks/week - unstable doses of psychotropics or phenothiazine - weight reducing medications - use of medications for erectile dysfunction during study period - pregnant, breast feeding, or planning pregnancy during study period - chronic disease that may interfere with participation - history of organ transplant - any serious illness that would interfere with participation or make DASH diet unsafe - planning to leave the area during the study period - significant food allergies, preferences, or dietary requirements that would interfere with diet adherence - investigator discretion for safety or compliance reasons |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Stedman Nutrition and Metabolism Center, Center for Living | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in blood pressure | A comparison of pre-intervention and post-intervention office diastolic blood pressure and 24 hour ambulatory systolic and diastolic blood pressure will be completed. | 2 weeks post DASH diet intervention | Yes |
Other | Change in markers of kidney function | A comparison of pre-intervention and post-intervention markers of kidney function (creatinine, eGFR, and urine albumin-to-creatinine ratio) will be completed. | 2 weeks post DASH diet intervention | Yes |
Other | Change in markers of mineral metabolism | A comparison of pre-intervention and post-intervention markers of mineral metabolism (calcium, phosphorus, intact parathyroid hormone, and 25-hydroxyvitamin D) will be completed. | 2 weeks post DASH diet intervention | No |
Other | Change in serum electrolytes | A comparison of pre-intervention and post-intervention electrolytes (bicarbonate, urea nitrogen) will be completed. | 2 weeks post DASH diet intervention | No |
Other | Change in fasting glucose | A comparison of pre-intervention and post-intervention fasting glucose will be completed. | 2 weeks post DASH diet intervention | No |
Other | Change in 24 hour urinary excretion | A comparison of pre-intervention and post-intervention urinary excretion of sodium, potassium, urea nitrogen, calcium, phosphorus, magnesium, creatinine, and albumin will be completed. | 2 weeks post DASH diet intervention | No |
Primary | Change in office systolic blood pressure | A comparison of pre-intervention and post-intervention systolic blood pressure will be completed. | 2 weeks post DASH diet intervention | Yes |
Secondary | Change in serum potassium | A comparison of pre-intervention and post-intervention serum potassium will be completed. | 2 weeks post DASH diet intervention | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |